Grifols SA ADR (GRFS)

NASD · Healthcare · Drug Manufacturers - General · Spain

Grifols SA ADR is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - General industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Grifols SA ADR stock.

Our verdict on GRFS

No reliable verdict: intrinsic value $86.06 per share, market price $8.63 (as of 2026-11-17).

Discounting its cash flows would put the shares at $86.06: 10 times the price of $8.63. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.

ETFs with the most weight in GRFS

1 more funds hold it; the full list is part of the paid plan.

Peers in Drug Manufacturers - General

All 21 Drug Manufacturers - General stocks

Is GRFS undervalued or overvalued?

We do not publish a verdict on GRFS. Discounting its cash flows would put the shares at $86.06: 10 times the price of $8.63. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.

What is the intrinsic value of GRFS?

We do not publish one (as of the 2026-11-17 close). Discounting its cash flows would put the shares at $86.06: 10 times the price of $8.63. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.